Randomised clinical trial: Alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 7, 2015, Pages 829-844

  Zeuzem, S ^a   Flisiak, R ^b   Vierling, J M ^b   Mazur, W ^b   Mazzella, G ^b   Thongsawat, S ^b   Abdurakhmanov, D ^b   Van Kinh N ^b   Calistru, P ^b   Heo, J ^b   Stanciu, C ^b   Gould, M ^b   Makara, M ^b   Hsu, S J ^b   Buggisch, P ^b   Samuel, D ^b   Mutimer, D ^b   Nault, B ^c   Merz, M ^c   Bao, W ^c   Griffel, L H ^c   Brass, C ^c   Naoumov, N V ^c   more..

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Novartis Pharma AG ^*  (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLOSPORIN; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BRONCHITIS; CHRONIC HEPATITIS C; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPERTRIGLYCERIDEMIA; LIVER CIRRHOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THROMBOCYTOPENIA; VOMITING; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84940788102     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13342     Document Type: Article

References (44)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. World Health Organization. Hepatitis C. Fact sheet N°164. April 2014. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed February 2015).
3. Feeney ER, Chung RT,. Antiviral treatment of hepatitis C. BMJ 2014; 349: g3308.
4. Kohli A, Shaffer A, Sherman A, Kottilil S,. Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631-40.
5. Hedenstierna M, Weiland O, Brass A, et al,. Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure. Aliment Pharmacol Ther 2015; 41: 532-43.
6. Rutter K, Stättermayer AF, Beinhardt S, et al,. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015; 41: 521-31.
7. Younossi Z, Henry L,. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41: 497-520.
8. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
11. Miller MH, Agarwal K, Austin A, et al,. Review article: 2014 UK consensus guidelines-hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39: 1363-75.
12. Gallay PA, Lin K,. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2013; 7: 105-15.
13. Chatterji U, Garcia-Rivera JA, Baugh J, et al,. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross resistance. Antimicrob Agents Chemother 2014; 58: 3327-34.
14. Naoumov NV,. Cyclophilin inhibition as potential therapy for liver diseases. J Hepatol 2014; 61: 1166-74.
15. Landrieu I, Hanoulle X, Bonachera F, et al,. Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry 2010; 49: 4679-86.
16. Flisiak R, Feinman SV, Jablkowski M, et al,. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009; 49: 1460-8.
17. Buti M, Flisiak R, Kao J-H, et al,. Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype-1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. J Viral Hepat 2015; 22: 596-606.
18. Pawlotsky JM, Sarin SK, Foster GR, et al,. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naïve patients with HCV GT2 or GT3: final results from the VITAL-1 study. Hepatology 2012; 56 (Suppl. 4): 309A.
19. Chen J, Florian J, Carter W, et al,. Early sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5.
20. Guo T, Gelperin K, Senior J,. A tool to help you decide (detect potentially serious liver injury). March 2008. Available at: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm076777.pdf (accessed June 2015).
21. Watkins PB, Desai M, Berkowitz SD, et al,. Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34: 243-52.
22. Lin X, Parks D, Painter J, et al,. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations. Drug Saf 2012; 35: 865-75.
23. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
24. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
25. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
26. Manns M, Marcellin P, Poordad F, et al,. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
27. Goto K, Watashi K, Inoue D, Hijikata M, Shimotohno K,. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci 2009; 100: 1943-50.
28. Coelmont L, Hanoulle X, Chatterji U, et al,. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE 2010; 5: e13687.
29. Puyang X, Poulin DL, Mathy JE, et al,. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 2010; 54: 1981-7.
30. Garcia-Rivera JA, Bobardt M, Chatterji U, et al,. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother 2012; 56: 5113-21.
31. Griffel L, Bao W, Orsenigo R, et al,. Interferon (IFN)-free alisporivir (ALV) has a better overall safety profile compared to IFN-containing treatment: a pooled analysis of the ALV development program. J Hepatol 2013; 58 (Suppl. 1): S336-7.
32. Chaudhari S, Park J, Anand BS, et al,. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci 2004; 49: 1000-6.
33. da Sila J, Giroldi SB, de Oliveira Basso F, et al,. Acute pancreatitis during interferon-alpha and ribavirin treatment for hepatitis C. BMJ Case Rep 2009; pii: bcr09.2008.0998.
34. Ando K, Kim SR, Imoto S, et al,. Acute pancreatitis associated with pegylated interferon and ribavirin treatment of chronic hepatitis C, genotype 1b with high viral load. Case Rep Gastroenterol 2009; 3: 372-36.
35. Pharmacist's Letter/Prescriber's Letter. Drug-induced pancreatitis. April 2013. http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&fpt=2&dd=290403 (accessed June 2015).
36. Whitcomb D, Saul M, Yadav D,. Does hepatitis C (Hep C) and/or interferon (IFN) increase acute pancreatitis (AP) risk? Pancreas 2012; 41: 1413.
37. Ventura C, Urich R, Skinner S, et al,. First report of telaprevir-induced pancreatitis. Dig Dis Sci 2013; 58: 887-8.
38. Bilar JM, Carvalho-Filho RJ, Mota CF, Fucuta Pda S, Ferraz ML,. Acute pancreatitis associated with boceprevir: a case report. Braz J Infect Dis 2014; 18: 454-6.
39. Selvi Sabater P, Espuny Mirõ A, Muñoz Bertrán ED, Plaza Aniorte J,. [Possible telaprevir-induced pancreatitis. A case study]. Farm Hosp 2013; 37: 269-70.
40. Morio R, Imamura M, Fukuhara T, et al,. A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir/peginterferon/ribavirin. Nihon Shokakibyo Gakkai Zasshi 2014; 111: 1997-2003.
41. Osinusi A, Meissner EG, Lee YJ, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-11.
42. Fleischer R,. NDA 201-917. Telaprevir. Clinical Review. April 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/201917Orig1s000MedR.pdf (accessed June 2015).
43. Quarato G, D'Aprile A, Gavillet B, et al,. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology 2012; 55: 1333-43.
44. Brees D, Cordier A, Mahl A, et al,. Alisporivir treatment does not cause or exacerbate pancreatitis when co-administered with interferon-alpha and/or ribavirin in the cerulein-induced pancreatitis rat model. Hepatology 2013; 58 (Suppl. 1): 436A.